Swedish Firms Pledpharma And RTT Merge To Target Orphan Drug Space
Two Late-Stage Assets For Rare Diseases
Following the failure of PledOx, Pledpharma is joining forces with Rare Thyroid Therapeutics to target orphan treatments, initially focusing on the latter's investigational therapy for MCT8 deficiency.
